Marlborough drugmaker Phio Pharmaceuticals has begun animal studies on an antiviral compound as a potential treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
The studies will investigate Phio’s INTASYL technology, a proprietary self-delivering RNAi therapeutic platform, for treating SARS-CoV-2 infection in a mouse, according to the Phio announcement Tuesday. The therapy has already had positive findings in lab tests.
The INTASYL-based antiviral compounds are designed to be effective against existing and future variants, according to Phio.
